LUMINARI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.082
EU - Europa 11.596
AS - Asia 9.467
SA - Sud America 1.697
AF - Africa 207
OC - Oceania 73
Continente sconosciuto - Info sul continente non disponibili 9
Totale 50.131
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.781
GB - Regno Unito 4.264
CN - Cina 3.130
SG - Singapore 2.475
IT - Italia 1.901
DE - Germania 1.743
HK - Hong Kong 1.606
BR - Brasile 1.359
SE - Svezia 1.062
VN - Vietnam 632
RU - Federazione Russa 559
UA - Ucraina 496
TR - Turchia 436
FI - Finlandia 343
FR - Francia 287
KR - Corea 266
BG - Bulgaria 225
ID - Indonesia 171
CA - Canada 154
AR - Argentina 148
IN - India 147
JP - Giappone 144
NL - Olanda 133
IE - Irlanda 98
ES - Italia 81
MX - Messico 81
AU - Australia 65
PL - Polonia 64
ZA - Sudafrica 64
EC - Ecuador 62
AT - Austria 60
BD - Bangladesh 58
MA - Marocco 48
IQ - Iraq 45
CH - Svizzera 43
PK - Pakistan 43
CO - Colombia 36
LT - Lituania 36
EG - Egitto 34
BE - Belgio 31
IR - Iran 30
PT - Portogallo 29
MY - Malesia 28
AE - Emirati Arabi Uniti 27
IL - Israele 25
RO - Romania 25
SA - Arabia Saudita 25
BZ - Belize 23
TW - Taiwan 23
PY - Paraguay 22
KE - Kenya 21
CL - Cile 20
CZ - Repubblica Ceca 20
TH - Thailandia 19
JO - Giordania 18
UZ - Uzbekistan 17
PE - Perù 16
PH - Filippine 16
VE - Venezuela 16
AZ - Azerbaigian 12
DZ - Algeria 12
NO - Norvegia 12
AL - Albania 11
DK - Danimarca 11
LB - Libano 11
NP - Nepal 10
TN - Tunisia 10
UY - Uruguay 10
KZ - Kazakistan 9
LV - Lettonia 9
PA - Panama 9
BH - Bahrain 8
HU - Ungheria 8
BO - Bolivia 7
CR - Costa Rica 7
GR - Grecia 7
NZ - Nuova Zelanda 7
SK - Slovacchia (Repubblica Slovacca) 7
DO - Repubblica Dominicana 6
LU - Lussemburgo 6
OM - Oman 6
AM - Armenia 5
GE - Georgia 5
HN - Honduras 5
HR - Croazia 5
KG - Kirghizistan 5
RS - Serbia 5
EU - Europa 4
SI - Slovenia 4
SV - El Salvador 4
BF - Burkina Faso 3
TT - Trinidad e Tobago 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BY - Bielorussia 2
EE - Estonia 2
GP - Guadalupe 2
GT - Guatemala 2
IM - Isola di Man 2
Totale 50.091
Salva come PNG Salva come JPEG
Città #
Fairfield 3.243
Southend 3.027
Santa Clara 2.508
Ashburn 2.389
Woodbridge 1.849
Hong Kong 1.594
Singapore 1.551
Houston 1.437
Chandler 1.210
Seattle 1.182
Wilmington 1.117
Cambridge 1.063
Frankfurt am Main 1.022
Hefei 996
Jacksonville 926
Dearborn 813
Ann Arbor 785
London 647
Beijing 609
Nyköping 605
Chicago 561
Los Angeles 487
San Diego 310
Modena 259
New York 257
Ho Chi Minh City 240
Princeton 238
Sofia 224
Seoul 212
Izmir 207
Salt Lake City 206
Redwood City 193
Eugene 186
Shanghai 183
The Dalles 163
Buffalo 162
Milan 149
São Paulo 145
Dallas 142
Moscow 136
Helsinki 135
Jakarta 132
Manchester 123
Council Bluffs 119
Hanoi 116
Munich 104
Rome 99
Elk Grove Village 96
Dublin 87
Tampa 82
Columbus 80
Phoenix 74
Bremen 72
Tokyo 72
Bologna 71
Dong Ket 62
Falls Church 59
Sterling 58
Guangzhou 54
Des Moines 53
Boardman 51
San Jose 51
Warsaw 50
Lancaster 48
Brooklyn 47
Rio de Janeiro 44
Turin 44
San Francisco 43
Tappahannock 42
Toronto 42
Nuremberg 40
Philadelphia 40
Stockholm 40
Norwalk 39
Kilburn 38
Denver 37
Dulles 36
Kent 36
Montreal 36
Turku 36
Atlanta 35
Redondo Beach 35
Miami 34
Belo Horizonte 32
Istanbul 31
Amsterdam 30
Chennai 30
Palermo 30
Parma 29
Brussels 28
Changsha 27
Boston 25
Genoa 25
Johannesburg 25
Nanjing 25
Casablanca 24
Kunming 24
Paris 24
Belize City 23
Chiswick 23
Totale 36.380
Salva come PNG Salva come JPEG
Nome #
Survival of cancer patients in Italy [La sopravvivenza dei pazienti oncologici in Italia [La sopravvivenza dei pazienti oncologici in Italia] 813
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study 746
Veno-occlusive disease nurse management: Development of a dynamic monitoring tool by the GITMO nursing group 658
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 624
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 584
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 471
Il linfoma mantellare 460
T-cell lymphoma in South America and Europe. 460
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 441
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 426
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 407
Transformed follicular lymphoma 400
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 398
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 369
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 353
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 351
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 345
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 343
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 335
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 329
Prognosis of follicular lymphomas 324
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 323
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial 316
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 313
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 298
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 298
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 296
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 293
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 291
Pure red-cell aplasia and epoetin therapy 290
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 290
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 288
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 286
A Gene Expression–based Model to Predict Metabolic Response after Two Courses of ABVD in Hodgkin Lymphoma Patients 285
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 284
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study 279
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 278
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 271
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 267
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 266
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 263
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 263
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 262
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 262
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 260
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 259
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 256
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 256
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 255
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 251
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 250
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy 249
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 246
Bendamustine salvage therapy for T cell neoplasms 246
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 244
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials 243
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 243
Reply to H.J.A. Adams et al and E. Laffon et al 243
ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial 241
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi Study 241
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 240
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 239
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 238
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 238
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 238
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 236
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 235
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 235
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. 232
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 232
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 232
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 232
I tumori in Italia. Rapporto 2011: La sopravvivenza dei pazienti oncologici in Italia 232
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) 232
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. 231
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 230
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 230
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 230
Reply to T.P. Vassilakopoulos et al 229
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 226
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. 224
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 223
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 223
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale 223
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 222
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 221
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 221
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 220
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma 220
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 219
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 218
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 218
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients 218
Novel prognostic tools that identify high-risk follicular lymphoma 218
Prognostic tools in follicular lymphomas 217
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: A subset analysis of NCIC CTG LY12 215
Advances in Treatment of Follicular Lymphoma 215
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system 214
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 214
Totale 29.274
Salva come PNG Salva come JPEG
Categoria #
all - tutte 213.465
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 213.465
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.600 0 0 0 0 0 468 436 675 472 664 495 390
2021/20224.667 325 538 521 270 134 271 245 297 471 365 804 426
2022/20233.849 419 393 324 330 460 504 96 396 465 97 220 145
2023/20244.005 113 207 185 229 1.442 205 411 669 78 79 89 298
2024/20259.509 313 88 141 700 1.717 1.465 723 509 1.275 557 929 1.092
2025/20269.650 1.150 893 1.690 2.483 3.003 431 0 0 0 0 0 0
Totale 50.770